How Are Responsibilities Divided for Authorized Representatives in Overseas Registration of Sterile Consumables?

How Are Responsibilities Divided for Authorized Representatives in Overseas Registration of Sterile Consumables?

When registering sterile consumables overseas, the division of responsibilities with the authorized representative (or local agent) directly determines whether the registration certificate remains valid long term, whether products can clear customs smoothly, and who bears the regulatory communication obligations in the event of quality incidents. Companies should not view the authorized representative simply as an "intermediary that submits documents." First, they must determine whether the product is classified as a medical device, drug, or biological product in the target country, then determine the risk class and registration pathway, and assess whether existing NMPA registration data, CE technical documentation, FDA 510(k), or ISO 13485 quality system evidence can be reused.

The core responsibilities of an authorized representative include submitting the registration application to the regulatory authority, receiving regulatory inquiries, assisting in adverse event reporting, maintaining technical documentation, cooperating with post-market surveillance and product sampling, and handling localization compliance for labels, instructions for use, and packaging. A common risk is that the contract only states "registration agency" without specifying obligations for changes, renewals, recalls, or infringement liability, resulting in ambiguous certificate ownership or even being "held hostage" by the agency.

Companies should prepare key sterility evidence for sterile consumables, including sterilization validation, sterility assurance level, shelf life, and ethylene oxide residues. Before signing agreements, they should verify the agent's qualifications, service scope, and renewal capabilities, and lock down certificate ownership and document control in writing.

Applicable Scenarios and Core Issues

Exporting sterile consumables to overseas markets usually requires designating a local authorized representative or registration agent, such as the EU Authorized Representative in Europe, the U.S. Agent in the United States, local agents in Southeast Asian countries, and local registrants in GHWP member countries in the Middle East and Latin America.

The core issue is not "finding a name to hang on," but how responsibilities are divided. Because sterile consumables directly contact the human body, they are usually classified as high-risk or medium-high-risk medical devices. Regulatory authorities often define the duties of marketing authorization holders, importers, and authorized representatives more strictly than for ordinary consumables.

Before starting overseas registration, companies must determine whether the target country's regulations distinguish between the "applicant" and the "authorized representative" as two separate legal roles. Some countries require the overseas manufacturer to serve only as the provider of technical documentation, while the local authorized representative is the legal applicant. Others allow the overseas manufacturer to apply directly, with the authorized representative assuming only communication and agency duties.

Unclear division of responsibilities leads to three types of problems: the legal holder of the registration certificate is ambiguous, and regulators cannot identify the responsible party; when adverse events occur after market entry, it is unclear who is responsible for reporting to the regulator; and during product changes, renewals, or recalls, the authorized representative may refuse to cooperate or demand exorbitant fees.

Therefore, companies should systematically allocate responsibilities across five dimensions: product access, registration pathway, technical evidence, contract terms, and post-market maintenance—rather than adding terms after obtaining the certificate.

Registration Decision Logic

The first step is to determine whether the product falls within the scope of medical device regulation in the target country. Sterile consumables may include syringes, catheters, surgical packs, dressings, implants, or in vitro diagnostic devices. Classification dictionaries and regulatory boundaries vary by country.

The second step is to determine the risk class and registration pathway. Sterile consumables usually fall into Class II or Class III. Under the EU MDR, some may be Class I sterile products, but most are Class IIa or above. The U.S. FDA may manage them as Class II or Class III, while Southeast Asia and the Middle East each have their own risk classifications based on ASEAN or IMDRF frameworks.

The third step is to assess whether existing NMPA, CE, FDA, ISO 13485, MDSAP, or other market documentation can be reused. Key evidence for sterile consumables includes sterilization process validation, sterility performance testing, biocompatibility testing, shelf life validation, packaging integrity testing, ethylene oxide residue testing, and simulated use studies.

If CE technical documentation exists, it can usually serve as the core technical documentation for registration in GHWP member countries, but it must be translated into the local language and reformatted locally for summaries and risk analyses.

If only an NMPA registration certificate is available, clinical evaluation, sterilization validation, and risk management reports may need to be supplemented according to the target country's guidelines and cannot be directly translated and submitted.

The fourth step is to confirm technical documentation, performance validation, risk management, clinical evidence, labeling and instructions, local agent, authorized representative, and post-market maintenance requirements. The responsibilities of authorized representatives differ greatly by country. For example, the EU Authorized Representative is mandatory and bears legal liability; Saudi Arabia's national single registration system requires foreign manufacturers to designate a local authorized representative; and some Southeast Asian countries require local agents to hold import licenses.

Companies should create a "responsibility matrix" based on the target country's regulatory framework, listing the obligations of the manufacturer, authorized representative, importer, and distributor, and attach it as an annex to the contract.

Documentation and Evidence

In overseas registration of sterile consumables, the authorized representative typically needs to co-sign a series of documents with the manufacturer, including the registration application form, power of attorney, declaration of conformity, technical documentation summary, sample labels and instructions for use, copies of quality system certificates, and sterilization process validation reports.

Core sterility evidence that the manufacturer must provide includes: sterilization process qualification reports, sterility release test standards, bioburden testing, pyrogen tests, particulate contamination testing, packaging integrity validation, shelf life stability data, and ethylene oxide residue test reports.

If the product has been certified under ISO 11135, ISO 11137, or ISO 13485, these certificates and audit reports can serve as baseline evidence for the authorized representative's communications with regulatory authorities.

Authorized representatives often require a "product technical documentation package," including product description, design inputs/outputs, risk management reports, clinical evaluation or exemption justifications, labels, and instructions for use.

When registering in GHWP member countries and countries along the "Belt and Road," authorized representatives often require a Free Sale Certificate from the country of origin. Therefore, domestic companies should apply for the relevant certificate from the Chinese NMPA or trade promotion agencies in advance.

Companies should also prepare a memorandum of authorization scope for the authorized representative, clearly stating whether the representative has the authority to sign supplementary agreements, receive adverse event reports, attend on-site audits on the manufacturer's behalf, and whether they may modify technical documentation without prior written consent from the manufacturer.

For multi-country registration, it is recommended to use one "master technical file" as the baseline and generate localized versions for each country's template, avoiding the need to regenerate a full set of sterilization validation documents for each registration.

Common Mistakes

• Treating the authorized representative as a "one-time registration agent" and losing contact after registration, resulting in no one following up on label changes and annual notifications.
• Not specifying certificate ownership in the contract. The certificate is registered in the authorized representative's name, but the document does not state that the manufacturer owns the technical documentation.
• Confusing the roles of authorized representative and importer or distributor. A representative appointed by a local distributor is mistaken for the manufacturer's own authorized representative, breaking the regulatory communication chain.
• Not clarifying the fee structure. High service fees are added later for renewals, changes, or recalls, leaving the manufacturer in a passive position.
• Assuming the authorized representative handles all regulatory affairs, when in fact many countries require the manufacturer to bear ultimate responsibility for technical documentation and clinical evidence.
• Ignoring the local qualifications and regulatory track record of the authorized representative, selecting an agent with no physical office or no experience dealing with health authorities.
• Failing to notify the authorized representative when the sterilization method for sterile consumables changes, leading to discrepancies between the registration file and actual processes during post-market inspections.
• Not including data protection, confidentiality, and liability clauses in the contract, leading to mutual blame in the event of adverse events or recalls.

Company Preparation Checklist

• Create a list of target countries, noting each country's regulatory authority, risk classification, registration pathway, and authorized representative requirements.
• Review existing certificates and validation documents, marking which can be directly reused, which need translation and notarization, and which must be re-performed according to local requirements.
• Compile a technical documentation directory for sterile consumables, including at least product instructions, drawings, sterilization validation, performance validation, risk analysis, labels, and instructions for use.
• Draft a screening questionnaire for authorized representatives, covering qualification, office address, responsiveness, service scope, renewal fees, and past adverse event handling cases.
• Develop a template agreement for authorized representatives that covers registration applications, document submission, change notifications, adverse event reporting, payment, renewal, dispute resolution, and exit mechanisms.
• For each registration certificate, clarify two roles: "certificate owner" and "technical documentation controller," ensuring clear ownership of trademarks, patents, and trade secrets.
• Assign internal regulatory personnel to periodically review regulatory updates with the authorized representative, especially ISO standards and local announcements related to sterile consumables.
• Establish a post-market surveillance file template, including customer complaint records, adverse event reports, withdrawal and recall procedures, and defining the authorized representative's response times.

AIMEILI Perspective

The most common misjudgment is the belief that "if you find a local agent, registration and compliance are entirely the agent's responsibility." In reality, most regulatory systems recognize the overseas manufacturer as ultimately responsible for product safety. The authorized representative's role is more like a "local compliance sentinel" and cannot replace the manufacturer's product quality responsibility.

Early in a project, companies should perform a "responsibility matrix analysis," comparing the target country's registration requirements, the authorized representative's statutory duties, and contract terms item by item. Then decide whether to use a single group representative for multiple countries or designate separate local representatives for each country. It is not advisable to have the distributor double as the authorized representative to save costs, as the distributor's commercial interests can compromise regulatory neutrality.

Reusable documentation includes ISO 13485 certificates, sterilization validation reports, biocompatibility evaluation reports, and CE technical documentation. Documentation that must be localized includes label language, symbols on labels, local registration formats, Free Sale Certificate authentication, and declaration of conformity templates.

Local agents, certificate control, changes, and renewals are critical because if the certificate lapses, the product may be delisted and imports halted. After approval, companies should establish an "annual compliance confirmation" mechanism with the authorized representative to verify the product list, label versions, sterilization processes, and manufacturing site each year. Any changes should be evaluated in advance for whether they require notification to the regulatory authority.

For multi-country registration, it is recommended to use a "master file + local supplementary package" approach. Start with a complete set of technical documentation as the basis, then generate independent registration summaries and localized appendices tailored to each target country. This significantly reduces the burden of repeated compilation and corrections, and also reduces additional review requests from authorized representatives due to incomplete documentation.

Common Follow-up Questions

Can the authorized representative and the local distributor be the same company?

Yes, it is possible, but it is strongly recommended to separate them or to clearly define the duties and scope of each role in the contract. The distributor is a commercial channel, while the authorized representative is the regulatory communication channel. Combining the two can lead to information distortion and conflicts of interest, especially in adverse event reporting, where the distributor may prioritize sales performance and hide problems.

If the authorized representative changes, does the original registration certificate remain valid?

It depends on the country. Under the EU MDR, changing the authorized representative requires a change application, and the new representative must obtain copies of the technical documentation during the transition period. Some Southeast Asian countries allow the certificate to be transferred through a change filing, but the manufacturer must prepare a handover certificate between the old and new representatives. If the change is not completed in advance, the registration certificate may be suspended or revoked.

Do sterilization validation documents for sterile consumables need to be issued in English by the laboratory for overseas registration?

Not necessarily all documents need to be in English, but regulatory authorities generally require test reports in the official language of the target country or an internationally accepted language. If the original reports are in Chinese, it is recommended that a qualified third-party testing agency or laboratory issue English versions, and have them notarized or authenticated by the embassy. Otherwise, the authorized representative will be unable to use Chinese reports to respond to local on-site audits.

Last updated: 2026-08-05